RxDoctor Payments Data

Elizabeth Nooney

Family · Cheyenne, WYNPI 1699323535

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.2% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Amgen at 30.5% of the total.

$1,121in general payments, 2019–2025

Across 47 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$342
  • Mallinckrodt Hospital Products Inc.$210
  • UCB, Inc.$149
  • Johnson & Johnson$125
  • AbbVie$100
  • Radius Health, Inc.$39
  • plus $156 from 8 others

What the payments were for

  • Food & beverage$1,02291%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,121 in reported general payments places this provider in the 80th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$30,693
Medicare patients
478
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ForteoTeriparatide29$123,932
Cosentyx Unoready PenSecukinumab13$90,537
Hydroxychloroquine Sulfate138$7,466
MethotrexateMethotrexate Sodium127$3,040
Leflunomide25$2,042
Sulfasalazine51$1,281
Pilocarpine Hcl17$915
Sulfasalazine DrSulfasalazine24$904
Celecoxib31$804
Alendronate Sodium81$764
Prednisone99$526
Duloxetine Hcl17$465
Meloxicam29$195
Pregabalin17$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo$26$123,93229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 284 family providers in Wyoming.

Other family in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →